Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.6% | +20.3% |
| SUNSHINE, HANNAH LOUISE | 1 | 71.0% | +13.3% |
| CHUNDURU, SURYAPRABHA | 1 | 53.4% | +17.4% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| BAUSCH, SARAE L | 1 | 29.0% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919711 | KIT AND SYSTEM FOR EVALUATING GLIOMA AND/OR GASTRIC ADENOCARCINOMA PROGNOSIS | GRAY, JESSICA | 93d overdue |
| 17919118 | cDNA, mRNA, PROTEIN, AND KIT AND SYSTEM FOR EVALUATING GLIOMA PROGNOSIS | BAUSCH, SARAE L | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018778 | ANTI-CD133 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING TUMOR | OUSPENSKI, ILIA I | 46d overdue |
| 17919704 | KIT FOR EVALUATING SENSITIVITY OF PATIENT TO MET INHIBITOR | CHUNDURU, SURYAPRABHA | 31d overdue |
| 17919118 | cDNA, mRNA, PROTEIN, AND KIT AND SYSTEM FOR EVALUATING GLIOMA PROGNOSIS | BAUSCH, SARAE L | 4d overdue |
| 18018711 | ANTI-TIM3 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARING MEDICINE FOR TREATING TUMOR | SUNSHINE, HANNAH LOUISE | 30d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1647 | 1 |
| 1681 | 1 |
| 1682 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18018778 | ANTI-CD133 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING TUMOR | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 46d overdue | Pending | Jan 30, 2023 |
| 18018711 | ANTI-TIM3 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARING MEDICINE FOR TREATING TUMOR | SUNSHINE, HANNAH LOUISE | 1647 | §103 | Final Rejection | 30d | Pending | Jan 30, 2023 |
| 17919704 | KIT FOR EVALUATING SENSITIVITY OF PATIENT TO MET INHIBITOR | CHUNDURU, SURYAPRABHA | 1681 | §103 | Final Rejection | 31d overdue | Pending | Oct 18, 2022 |
| 17919711 | KIT AND SYSTEM FOR EVALUATING GLIOMA AND/OR GASTRIC ADENOCARCINOMA PROGNOSIS | GRAY, JESSICA | 1682 | Other | Non-Final OA | 93d overdue | Pending | Oct 18, 2022 |
| 17919118 | cDNA, mRNA, PROTEIN, AND KIT AND SYSTEM FOR EVALUATING GLIOMA PROGNOSIS | BAUSCH, SARAE L | 1699 | Other | Final Rejection | 4d overdue | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial